SCHEMBL799359

SCHEMBL799359

COc1cncc(-c2cc(NC(=O)Nc3ccccc3C(=O)NC(C)C)nn2C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.46
▸ POLB P06746 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ HTT P42858 2/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ ADORA2B P29275 2/20 0.39
▸ ADORA1 P30542 2/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ MEN1 O00255 4/20 0.39
▸ KMT2A Q03164 4/20 0.39
▸ PKM P14618 3/20 0.39
▸ ABCG2 Q9UNQ0 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ NPC1 O15118 3/20 0.38
▸ RAB9A P51151 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL798969 0.84 MAPK1 (0.43) ALDH1A1KDM4EHTTSMN1; SMN2HSD17B10
SCHEMBL798739 0.81 KDM4E (0.41) ALDH1A1KDM4ESMN1; SMN2ADORA2BADORA1
SCHEMBL798614 0.80 PDE4A (0.45) ALDH1A1POLBCYP1A2CYP3A4CYP2C9
SCHEMBL171590 0.79 RIPK1 (0.48) —
SCHEMBL805085 0.71 ALDH1A1 (0.40) ALDH1A1POLBCYP1A2CYP3A4CYP2C9
SCHEMBL799139 0.70 RIPK1 (0.48) KDM4EHTTMEN1KMT2A
SCHEMBL10392 0.67 PIK3CG (0.51) CYP2C9
SCHEMBL29614706 0.67 KDM4E (0.53) ALDH1A1POLBCYP1A2CYP3A4KDM4E
SCHEMBL19307111 0.67 KDM4E (0.53) ALDH1A1POLBCYP1A2CYP3A4KDM4E
SCHEMBL799302 0.65 RIPK1 (0.49) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-03-22 — — US disclosed
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY MTOR, STAT3, SLC14A1 ALDH1A1 3750/4885POLB 1335/4885CYP1A2 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback